Advanz Pharma

Company snapshot

Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In l

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Advanz Pharma. Not investment advice.

• What is Advanz Pharma?

  ADVANZ PHARMA is a pharma organization headquartered in London, GB. Primary therapeutic focus areas include Atrial Fibrillation. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPT

• Is Advanz Pharma publicly traded?

  Advanz Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Advanz Pharma develop or market?

  We link 1 drug profile(s) where Advanz Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/advanz-pharma-limited#company-drugs.

• What are the latest developments for Advanz Pharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Advanz Pharma focus on?

  Advanz Pharma focuses on Atrial Fibrillation based on our analysis of their pipeline programs and drug development activities.